Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5947302 | 0.89 | MAPK1 (0.56) | MAPK1SCN8ABCHETDP1ALDH1A1 | |
| SCHEMBL14197917 | 0.88 | ALDH1A1 (0.62) | MAPK1SCN8ABCHETDP1L3MBTL1 | |
| SCHEMBL14197925 | 0.86 | MAPK1 (0.69) | MAPK1BCHETDP1ALDH1A1TP53 | |
| SCHEMBL14197926 | 0.85 | BCHE (0.67) | MAPK1BCHECHRM2CYP2D6 | |
| SCHEMBL10235855 | 0.79 | TSHR (0.52) | MAPK1TDP1L3MBTL1KMT2ACYP2D6 | |
| SCHEMBL13106257 | 0.78 | TDP1 (0.58) | MAPK1TDP1L3MBTL1ALDH1A1POLB | |
| SCHEMBL13645863 | 0.78 | HSD17B10 (0.52) | MAPK1TDP1L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL3738479 | 0.77 | CYP1A2 (0.71) | SCN8ATDP1L3MBTL1ALDH1A1TP53 | |
| SCHEMBL5947434 | 0.77 | BCHE (0.58) | MAPK1BCHEALDH1A1KMT2ACYP2D6 | |
| SCHEMBL14197923 | 0.76 | SMN1; SMN2 (0.65) | MAPK1BCHEALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | MAPK1 1152/4885SCN8A 4695/4885BCHE 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.